Use of rapamycin in the induction of tolerogenic dendritic cells

Angus W. Thomson; Ryan Fischer; Heth R. Turnquist; Timuçin Taner

doi:10.1007/978-3-540-71029-5-10

Use of rapamycin in the induction of tolerogenic dendritic cells

Angus W. Thomson, Ryan Fischer, Heth R. Turnquist, Timuçin Taner

Transplant Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

47 Scopus citations

Abstract

Rapamycin (RAPA), a macrocyclic triene antibiotic pro-drug, is a clinically-utilized 'tolerance-sparing' immunosuppressant that inhibits the activity of T, B, and NK cells. Furthermore, maturation-resistance and tolerogenic properties of dendritic cells (DC) can be supported and preserved by conditioning with RAPA. Propagation of murine bone marrow (BM)-derived myeloid DC (mDC) in clinically relevant concentrations of RAPA (RAPA-DC) generates phenotypically immature DC with low levels of MHC and significantly reduced co-stimulatory molecules (especially CD86), even when exposed to inflammatory stimuli. RAPA-DC are weak stimulators of T cells and induce hyporesponsiveness and apoptosis in allo-reactive T cells. An interesting observation has been that RAPA-DC retain the ability to stimulate and enrich the regulatory T cells (Treg). Presumably as a result of these properties, alloantigen (alloAg)-pulsed recipient-derived DC are effective in subverting anti-allograft immune responses in rodent transplant models, making them an attractive subject for further investigation of their tolerance-promoting potential.

Original language	English (US)
Title of host publication	Dendritic Cells
Pages	215-232
Number of pages	18
DOIs	https://doi.org/10.1007/978-3-540-71029-5-10
State	Published - 2009

Publication series

Name	Handbook of Experimental Pharmacology
Volume	188
ISSN (Print)	0171-2004

ASJC Scopus subject areas

Biochemistry
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1007/978-3-540-71029-5-10

Fingerprint Dive into the research topics of 'Use of rapamycin in the induction of tolerogenic dendritic cells'. Together they form a unique fingerprint.

Cite this

@inbook{ed6f478dfe60484ebab168feb6de49b1,

title = "Use of rapamycin in the induction of tolerogenic dendritic cells",

abstract = "Rapamycin (RAPA), a macrocyclic triene antibiotic pro-drug, is a clinically-utilized 'tolerance-sparing' immunosuppressant that inhibits the activity of T, B, and NK cells. Furthermore, maturation-resistance and tolerogenic properties of dendritic cells (DC) can be supported and preserved by conditioning with RAPA. Propagation of murine bone marrow (BM)-derived myeloid DC (mDC) in clinically relevant concentrations of RAPA (RAPA-DC) generates phenotypically immature DC with low levels of MHC and significantly reduced co-stimulatory molecules (especially CD86), even when exposed to inflammatory stimuli. RAPA-DC are weak stimulators of T cells and induce hyporesponsiveness and apoptosis in allo-reactive T cells. An interesting observation has been that RAPA-DC retain the ability to stimulate and enrich the regulatory T cells (Treg). Presumably as a result of these properties, alloantigen (alloAg)-pulsed recipient-derived DC are effective in subverting anti-allograft immune responses in rodent transplant models, making them an attractive subject for further investigation of their tolerance-promoting potential.",

author = "Thomson, {Angus W.} and Ryan Fischer and Turnquist, {Heth R.} and Timu{\c c}in Taner",

year = "2009",

doi = "10.1007/978-3-540-71029-5-10",

language = "English (US)",

isbn = "9783540710288",

series = "Handbook of Experimental Pharmacology",

pages = "215--232",

booktitle = "Dendritic Cells",

}

TY - CHAP

T1 - Use of rapamycin in the induction of tolerogenic dendritic cells

AU - Thomson, Angus W.

AU - Fischer, Ryan

AU - Turnquist, Heth R.

AU - Taner, Timuçin

PY - 2009

Y1 - 2009

N2 - Rapamycin (RAPA), a macrocyclic triene antibiotic pro-drug, is a clinically-utilized 'tolerance-sparing' immunosuppressant that inhibits the activity of T, B, and NK cells. Furthermore, maturation-resistance and tolerogenic properties of dendritic cells (DC) can be supported and preserved by conditioning with RAPA. Propagation of murine bone marrow (BM)-derived myeloid DC (mDC) in clinically relevant concentrations of RAPA (RAPA-DC) generates phenotypically immature DC with low levels of MHC and significantly reduced co-stimulatory molecules (especially CD86), even when exposed to inflammatory stimuli. RAPA-DC are weak stimulators of T cells and induce hyporesponsiveness and apoptosis in allo-reactive T cells. An interesting observation has been that RAPA-DC retain the ability to stimulate and enrich the regulatory T cells (Treg). Presumably as a result of these properties, alloantigen (alloAg)-pulsed recipient-derived DC are effective in subverting anti-allograft immune responses in rodent transplant models, making them an attractive subject for further investigation of their tolerance-promoting potential.

AB - Rapamycin (RAPA), a macrocyclic triene antibiotic pro-drug, is a clinically-utilized 'tolerance-sparing' immunosuppressant that inhibits the activity of T, B, and NK cells. Furthermore, maturation-resistance and tolerogenic properties of dendritic cells (DC) can be supported and preserved by conditioning with RAPA. Propagation of murine bone marrow (BM)-derived myeloid DC (mDC) in clinically relevant concentrations of RAPA (RAPA-DC) generates phenotypically immature DC with low levels of MHC and significantly reduced co-stimulatory molecules (especially CD86), even when exposed to inflammatory stimuli. RAPA-DC are weak stimulators of T cells and induce hyporesponsiveness and apoptosis in allo-reactive T cells. An interesting observation has been that RAPA-DC retain the ability to stimulate and enrich the regulatory T cells (Treg). Presumably as a result of these properties, alloantigen (alloAg)-pulsed recipient-derived DC are effective in subverting anti-allograft immune responses in rodent transplant models, making them an attractive subject for further investigation of their tolerance-promoting potential.

UR - http://www.scopus.com/inward/record.url?scp=60549107773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549107773&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-71029-5-10

DO - 10.1007/978-3-540-71029-5-10

M3 - Chapter

C2 - 19031028

AN - SCOPUS:60549107773

SN - 9783540710288

T3 - Handbook of Experimental Pharmacology

SP - 215

EP - 232

BT - Dendritic Cells

ER -

Use of rapamycin in the induction of tolerogenic dendritic cells

Abstract

Publication series

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this